The FDA has recently granted orphan drug designation to Ezurpimtrostat, a PPT-1 inhibitor for the treatment of patients with hepatocellular carcinoma (HCC).
Many lung cancer patients will be detected by genetic testing to carry an EGFR mutation, and these patients can often control their tumours with EGFR-targeted drugs. Although targeted drugs are effective and have fewer side effects than chemotherapy, resistance to them inevitably occurs, after which they no longer work.
Pancreatic cancer is known to be a highly fatal and incurable type of cancer known as the "king of cancers". Currently, the only possible cure for pancreatic cancer is the complete surgical removal of the tumour tissue. Once the cancer has spread beyond the pancreatic organ, the patient's treatment options are very limited.
Many elderly people have high blood pressure themselves, but refuse to stick to their antihypertensive medication, thinking that taking it for a long time will have many side effects.
The global ADC drug market will be approximately $5.2 billion by 2021
With more and more new cutting-edge drugs emerging, the standard treatment paradigm for breast cancer is now rapidly changing, and the future is looking brighter for patients.
Eisai and Biogen have partnered to develop Leqembi and have priced it at $26,500 per year.
H-Drugs in the leading international journal again!
The FDA granted priority review status to Enhertu (DS-8201) for the treatment of patients with HR-positive, low HER2-expressing breast cancer, and Enhertu has enabled these patients to remain disease-free for an average of 10.1 months, with an average overall survival time of nearly two years. A decision on approval is expected to be made in the fourth quarter of this year.
The US FDA has approved pemigatinib, the first targeted drug to date for patients with specific mutated blood tumours, and the results of the study show that the drug made tumours disappear completely in 79% of patients!
